source
- Late-stage mRNA melanoma vaccine shows promise, slowing disease recurrenceA late-stage trial of an mRNA-based cancer vaccine reported that the treatment halted the return of melanoma in patients, providing the first clear evidence of efficacy for this approach. Merck an…
- Genentech signs up to develop Alector’s preclinical blood-brain barrier therapy in $1.27 billion dealGenentech, a Roche subsidiary, announced a deal with Alector to obtain exclusive rights to its preclinical blood-brain barrier delivery asset, AL050. The agreement provides $100 million upfront an…